Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, produced by Streptomyces strains | 2481 | 57-92-1 |
Dose | Unit | Route |
---|---|---|
1 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 20 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 55 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 34.39 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 1 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.34 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 0.78 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.65 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 4.30 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 18, 1946 | FDA | PFIZER |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Paradoxical drug reaction | 64.60 | 36.14 | 13 | 503 | 4139 | 63484367 |
Drug reaction with eosinophilia and systemic symptoms | 62.09 | 36.14 | 19 | 497 | 33817 | 63454689 |
Drug resistance | 38.30 | 36.14 | 12 | 504 | 22921 | 63465585 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Paradoxical drug reaction | 128.39 | 47.30 | 27 | 881 | 3324 | 34952699 |
Drug resistance | 92.78 | 47.30 | 32 | 876 | 25895 | 34930128 |
Immune reconstitution inflammatory syndrome | 79.07 | 47.30 | 22 | 886 | 8737 | 34947286 |
Tuberculoma of central nervous system | 77.69 | 47.30 | 12 | 896 | 252 | 34955771 |
Immune reconstitution inflammatory syndrome associated tuberculosis | 64.20 | 47.30 | 11 | 897 | 447 | 34955576 |
Pathogen resistance | 51.17 | 47.30 | 16 | 892 | 9466 | 34946557 |
Hepatitis cholestatic | 49.62 | 47.30 | 15 | 893 | 7932 | 34948091 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Paradoxical drug reaction | 185.38 | 38.37 | 39 | 1358 | 7146 | 79735845 |
Drug resistance | 124.96 | 38.37 | 41 | 1356 | 42172 | 79700819 |
Immune reconstitution inflammatory syndrome associated tuberculosis | 89.07 | 38.37 | 15 | 1382 | 821 | 79742170 |
Immune reconstitution inflammatory syndrome | 86.72 | 38.37 | 24 | 1373 | 13817 | 79729174 |
Tuberculoma of central nervous system | 79.92 | 38.37 | 13 | 1384 | 574 | 79742417 |
Pathogen resistance | 67.93 | 38.37 | 20 | 1377 | 14322 | 79728669 |
Drug reaction with eosinophilia and systemic symptoms | 60.16 | 38.37 | 27 | 1370 | 64217 | 79678774 |
Drug-induced liver injury | 56.27 | 38.37 | 26 | 1371 | 66091 | 79676900 |
Conductive deafness | 44.80 | 38.37 | 7 | 1390 | 238 | 79742753 |
None
Source | Code | Description |
---|---|---|
ATC | A07AA04 | ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS INTESTINAL ANTIINFECTIVES Antibiotics |
ATC | A07AA54 | ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS INTESTINAL ANTIINFECTIVES Antibiotics |
ATC | J01GA01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE AMINOGLYCOSIDE ANTIBACTERIALS Streptomycins |
ATC | J04AM01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis |
FDA CS | M0000946 | Aminoglycosides |
FDA EPC | N0000175477 | Aminoglycoside Antibacterial |
FDA EPC | N0000175483 | Antimycobacterial |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D011500 | Protein Synthesis Inhibitors |
CHEBI has role | CHEBI:33281 | antibiotics |
CHEBI has role | CHEBI:36043 | antimicrobial drugs |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
CHEBI has role | CHEBI:48001 | protein synthesis inhibitors |
CHEBI has role | CHEBI:86328 | anti-fungal agrichemical |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Tularemia | indication | 19265001 | |
Acute tuberculosis | indication | 25629007 | |
Granuloma inguinale | indication | 28867007 | DOID:9113 |
Plague | indication | 58750007 | DOID:3482 |
Klebsiella cystitis | indication | 60867007 | |
Haemophilus influenzae pneumonia | indication | 70036007 | |
Brucellosis | indication | 75702008 | DOID:11077 |
Pulmonary tuberculosis | indication | 154283005 | DOID:2957 |
Chancroid | indication | 266143009 | DOID:13778 |
Escherichia coli urinary tract infection | indication | 301011002 | |
Proteus urinary tract infection | indication | 301012009 | |
Bacterial urinary infection | indication | 312124009 | |
Aerobic Gram-Negative Bacteremia | indication | ||
Synergy for Streptococcal Endocarditis | indication | ||
Haemophilus Endocarditis | indication | ||
Synergy for Enterococcal Endocarditis | indication | ||
Enterococcus Urinary Tract Infection | indication | ||
Synergy for Enterococcal Infections | indication | ||
H. Influenzae Meningitis | indication | ||
Pulmonary Mycobacterium avium complex infection | off-label use | 186342000 | |
Hypocalcemia | contraindication | 5291005 | |
Parkinsonism | contraindication | 32798002 | |
Dehydration | contraindication | 34095006 | |
Tinnitus | contraindication | 60862001 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Myasthenia gravis | contraindication | 91637004 | DOID:437 |
Pregnancy, function | contraindication | 289908002 | |
Vertigo | contraindication | 399153001 | |
Inner Ear Disturbance | contraindication | ||
Disorder of the 8th Cranial Nerve | contraindication | ||
Infant Botulism | contraindication |
Species | Use | Relation |
---|---|---|
Cattle | Bacterial enteritis caused by Escherichia coli | Indication |
Cattle | Bacterial enteritis caused by Salmonella spp | Indication |
Chickens | Nonspecific infectious enteritis caused by bacteria | Indication |
Swine | Bacterial enteritis caused by Escherichia coli | Indication |
Swine | Bacterial enteritis caused by Salmonella spp | Indication |
Product | Applicant | Ingredients |
---|---|---|
Entromycin Powder | Zoetis Inc. | 2 |
STREP SOL | Huvepharma EOOD | 1 |
Streptomycin Oral Solution | Huvepharma EOOD | 1 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 12.43 | acidic |
pKa2 | 12.62 | acidic |
pKa3 | 13.36 | acidic |
pKa4 | 13.79 | acidic |
pKa5 | 11.91 | Basic |
pKa6 | 11.21 | Basic |
pKa7 | 6.49 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
30S ribosomal protein S12 | Ribosomal protein | WOMBAT-PK |
ID | Source |
---|---|
4019933 | VUID |
N0000148018 | NUI |
D01350 | KEGG_DRUG |
3810-74-0 | SECONDARY_CAS_RN |
4017475 | VANDF |
4019933 | VANDF |
C0038425 | UMLSCUI |
CHEBI:58007 | CHEBI |
SRY | PDB_CHEM_ID |
CHEMBL372795 | ChEMBL_ID |
CHEMBL453087 | ChEMBL_ID |
CHEMBL3184791 | ChEMBL_ID |
D013307 | MESH_DESCRIPTOR_UI |
DB01082 | DRUGBANK_ID |
10923 | IUPHAR_LIGAND_ID |
3685 | INN_ID |
Y45QSO73OB | UNII |
19649 | PUBCHEM_CID |
10109 | RXNORM |
1794 | MMSL |
5514 | MMSL |
d00159 | MMSL |
002770 | NDDF |
004895 | NDDF |
387223008 | SNOMEDCT_US |
40877002 | SNOMEDCT_US |
73246001 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Streptomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0706 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 21 sections |
Streptomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0706 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 21 sections |
Streptomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0706 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 21 sections |
Streptomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0706 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 21 sections |